Oruka Therapeutics (ORKA) Cash from Financing Activities (2010 - 2026)

Oruka Therapeutics' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $40.6 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $40.6 million in Q1 2026; TTM through Mar 2026 was $210.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $170.3 million, down 62.11% from the prior year.
• Cash from Financing Activities rose to $40.6 million in Q1 2026 per ORKA's latest filing, from $298000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $423.7 million in Q3 2024 and bottomed at -$1.6 million in Q2 2024.
• The 3-year median for Cash from Financing Activities is $27.9 million (2024), against an average of $94.3 million.
• Biggest YoY gain for Cash from Financing Activities was 156.65% in 2025; the steepest drop was 59.9% in 2025.
• Year by year, Cash from Financing Activities stood at -$526000.0 in 2024, then jumped by 156.65% to $298000.0 in 2025, then jumped by 13524.16% to $40.6 million in 2026.
• Per Business Quant, the three latest ORKA Cash from Financing Activities figures stand at $40.6 million (Q1 2026), $298000.0 (Q4 2025), and $169.9 million (Q3 2025).